Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.75.

A number of analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Mizuho cut their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Wall Street Zen raised shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 9th.

Autolus Therapeutics Trading Down 1.3%

Shares of Autolus Therapeutics stock opened at $1.51 on Friday. The company has a 50 day moving average of $1.58 and a 200-day moving average of $1.56. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.70. The company has a market cap of $401.90 million, a PE ratio of -1.39 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Research analysts forecast that Autolus Therapeutics will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter valued at approximately $28,000. Independent Advisor Alliance bought a new position in Autolus Therapeutics in the 4th quarter valued at approximately $28,000. SmartHarvest Portfolios LLC bought a new position in Autolus Therapeutics in the 4th quarter valued at approximately $43,000. Waverly Advisors LLC bought a new position in Autolus Therapeutics in the 1st quarter valued at approximately $37,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Autolus Therapeutics in the 3rd quarter valued at approximately $46,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.